Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Riboxx Pharmaceuticals and China National Biotec Group (CNBG) jointly announced that they have started a research collaboration to evaluate Riboxxim, a TLR3 agonist from Riboxx, with an antigen of CNBG against one of the world’s deadliest infectious diseases.
Subscribe to our email newsletter
As part of the research collaboration, Riboxx will provide access to Riboxxim to enable CNBG to perform an evaluation, in conjunction with CNBG’s antigen, against the disease target.
Riboxx CEO Dr. Jacques Rohayem said the firm is delighted to collaborate with CNBG, which is one of the leading developers of vaccines against serious infectious diseases.
"Our TLR3 agonist has the potential to increase the efficacy of the antigen and provide a safe but highly effective immune response against the disease," Rohayem added.